BioSpace10h
Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data
Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...
FierceBiotech15h
Inhibikase hits pause on Parkinson's program over efficacy as it prioritizes lung drug
Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...
biopharma-reporter9h
Setback for Inhibikase Parkinson’s therapy
Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.
Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study
Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...
Inhibikase Halts Parkinson's Drug Development to Focus on PAH
Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...
ENDPOINTS NEWS12h
In­hibikase shelves Parkin­son’s as­set af­ter Phase 2 flop
Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...
Yahoo Finance9d
Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock
Quite a few insiders have dramatically grown their holdings in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) over the past 12 months. An insider's optimism about the company's prospects is a positive ...